These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 19730691)

  • 1. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
    Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
    PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
    Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
    PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
    Blanchet FP; Mitchell JP; Piguet V
    Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.
    Tokarev AA; Munguia J; Guatelli JC
    J Virol; 2011 Jan; 85(1):51-63. PubMed ID: 20980512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
    Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.
    Schmidt S; Fritz JV; Bitzegeio J; Fackler OT; Keppler OT
    mBio; 2011; 2(3):e00036-11. PubMed ID: 21610122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.
    Waheed AA; Kuruppu ND; Felton KL; D'Souza D; Freed EO
    PLoS One; 2014; 9(10):e111628. PubMed ID: 25360760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
    Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
    PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
    Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
    J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.